1. Home
  2. MAGN vs CUVL Comparison

MAGN vs CUVL Comparison

Compare MAGN & CUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Magnera Corporation

MAGN

Magnera Corporation

HOLD

Current Price

$11.91

Market Cap

424.7M

ML Signal

HOLD

Logo Clinuvel Pharmaceuticals Limited American Depositary Shares

CUVL

Clinuvel Pharmaceuticals Limited American Depositary Shares

N/A

Current Price

$5.75

Market Cap

374.2M

Sector

Miscellaneous

ML Signal

N/A

Company Overview

Basic Information
Metric
MAGN
CUVL
Founded
1864
N/A
Country
United States
Australia
Employees
2980
16
Industry
Paper
Miscellaneous
Sector
Basic Materials
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
424.7M
374.2M
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
MAGN
CUVL
Price
$11.91
$5.75
Analyst Decision
Hold
Analyst Count
1
0
Target Price
★ $12.00
N/A
AVG Volume (30 Days)
★ 332.7K
20.9K
Earning Date
05-07-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
★ 7.64
N/A
EPS
N/A
★ N/A
Revenue
★ $3,204,000,000.00
N/A
Revenue This Year
$5.37
N/A
Revenue Next Year
$3.47
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 46.50
N/A
52 Week Low
$7.82
$5.60
52 Week High
$15.52
$8.20

Technical Indicators

Market Signals
Indicator
MAGN
CUVL
Relative Strength Index (RSI) 45.11 39.28
Support Level $11.54 $5.70
Resistance Level $11.91 $6.07
Average True Range (ATR) 0.36 0.16
MACD 0.05 0.00
Stochastic Oscillator 45.87 35.42

Price Performance

Historical Comparison
MAGN
CUVL

About MAGN Magnera Corporation

Magnera Corp is a supplier of a diverse portfolio of specialty materials comprised of organic and synthetic raw ingredients. The company markets its own products predominantly into stable, consumer-oriented end markets, including wipes, healthcare, adult incontinence, apparel, baby, feminine care, air filtration, and food and beverage, for disposable and durable applications. It also provides technical solutions in infrastructure markets. The company's operations are organized into two operating and reportable segments: Americas and Rest of World. It derives the majority of its revenue from the Americas, which manufactures products and components of personal care, including medical garments, wipes, dryer sheets, filtration, baby diapers and adult incontinence.

About CUVL Clinuvel Pharmaceuticals Limited American Depositary Shares

Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.

Share on Social Networks: